Hyperliquid Strategies’ (PURR) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Hyperliquid Strategies (NASDAQ:PURR) in a research report released on Thursday,Benzinga reports. They currently have a $9.75 target price on the stock.

Other equities research analysts also recently issued research reports about the company. Cantor Fitzgerald boosted their target price on Hyperliquid Strategies from $8.00 to $18.40 and gave the stock an “overweight” rating in a research report on Wednesday, July 1st. Weiss Ratings raised Hyperliquid Strategies from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.53.

Hyperliquid Strategies Stock Performance

NASDAQ:PURR opened at $11.61 on Thursday. The stock’s fifty day moving average price is $7.86 and its two-hundred day moving average price is $6.88. Hyperliquid Strategies has a 52-week low of $3.01 and a 52-week high of $14.14. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -1.58 and a beta of 1.71.

Hedge Funds Weigh In On Hyperliquid Strategies

Large investors have recently bought and sold shares of the business. Amundi bought a new position in Hyperliquid Strategies in the second quarter valued at approximately $190,000. California State Teachers Retirement System acquired a new stake in Hyperliquid Strategies during the 2nd quarter worth $107,000. SPX Gestao de Recursos Ltda bought a new stake in shares of Hyperliquid Strategies during the 2nd quarter valued at $860,000. Wellington Management Group LLP bought a new stake in shares of Hyperliquid Strategies during the 2nd quarter valued at $716,000. Finally, Paradigm Operations LP acquired a new position in shares of Hyperliquid Strategies in the 2nd quarter valued at $44,936,535. 9.45% of the stock is currently owned by institutional investors and hedge funds.

Key Hyperliquid Strategies News

Here are the key news stories impacting Hyperliquid Strategies this week:

• Positive Sentiment: Hyperliquid Strategies reported fiscal 2026 net income of approximately $305.5 million and highlighted major operational progress, including more than doubling its HYPE treasury, launching a large network validator and completing its exit from legacy biotech operations. Hyperliquid Strategies Inc Reports Financial Results for the Fiscal Year Ended June 30, 2026
• Positive Sentiment: The company disclosed a HYPE position valued at roughly $1.9 billion, with its treasury reportedly reaching about 29.3 million tokens. Investors appear to be treating the treasury as a direct way to gain exposure to the Hyperliquid ecosystem. Hyperliquid Strategies Shares Rise After Reporting $1.9B HYPE Position
• Positive Sentiment: HYPE reached a record price near $84.80, increasing the reported value of Hyperliquid Strategies’ token holdings and supporting the stock’s momentum. Hyperliquid HYPE Surges to Record $84.80
• Neutral Sentiment: Chardan Capital reaffirmed a Buy rating and raised its outlook, but its reported $9.75 price target is below the stock’s recent trading level, suggesting analysts may be lagging the rally or see limited near-term upside. Why Is Hyperliquid Strategies Stock Up on Friday?
• Negative Sentiment: Technical commentary warns that the HYPE rally may be becoming stretched, while the company’s results and valuation remain highly sensitive to cryptocurrency prices. A reversal in HYPE could reduce the value of PURR’s treasury and pressure the shares. Hyperliquid Price Forecast

About Hyperliquid Strategies

Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc, is based in NEW YORK.